These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38859848)

  • 21. AKT3 is a key regulator of head and neck squamous cell carcinoma.
    Takahashi H; Rokudai S; Kawabata-Iwakawa R; Sakakura K; Oyama T; Nishiyama M; Chikamatsu K
    Cancer Sci; 2021 Jun; 112(6):2325-2334. PubMed ID: 33811778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osthole induces cell cycle arrest and apoptosis in head and neck squamous cell carcinoma by suppressing the PI3K/AKT signaling pathway.
    Yang J; Zhu XJ; Jin MZ; Cao ZW; Ren YY; Gu ZW
    Chem Biol Interact; 2020 Jan; 316():108934. PubMed ID: 31870840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression profile analysis identifies a two-gene signature for prediction of head and neck squamous cell carcinoma patient survival.
    Xu X; Li M; Hu J; Chen Z; Yu J; Dong Y; Sun C; Han J
    J Cancer Res Ther; 2018; 14(7):1525-1534. PubMed ID: 30589034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identity of MMP1 and its effects on tumor progression in head and neck squamous cell carcinoma.
    Zhang G; Li T; Tan G; Song Y; Liu Q; Wang K; Ai J; Zhou Z; Li W
    Cancer Med; 2022 Jun; 11(12):2516-2530. PubMed ID: 35426219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
    Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
    Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel prognostic matrisome-related gene signature of head and neck squamous cell carcinoma.
    Huang C; Liang Y; Dong Y; Huang L; Li A; Du R; Huang H
    Front Cell Dev Biol; 2022; 10():884590. PubMed ID: 36081907
    [No Abstract]   [Full Text] [Related]  

  • 27. GAPDH: unveiling its impact as a key hypoxia-related player in head and neck squamous cell carcinoma tumor progression, prognosis, and therapeutic potential.
    Peng C; Ye H; Yi Z
    Am J Cancer Res; 2023; 13(12):5846-5867. PubMed ID: 38187058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blocking of stromal interaction molecule 1 expression influence cell proliferation and promote cell apoptosis in vitro and inhibit tumor growth in vivo in head and neck squamous cell carcinoma.
    Li P; Bian XY; Chen Q; Yao XF; Wang XD; Zhang WC; Tao YJ; Jin R; Zhang L
    PLoS One; 2017; 12(5):e0177484. PubMed ID: 28494008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long non-coding RNA HOTAIR/microRNA-206 sponge regulates STC2 and further influences cell biological functions in head and neck squamous cell carcinoma.
    Li T; Qin Y; Zhen Z; Shen H; Cong T; Schiferle E; Xiao S
    Cell Prolif; 2019 Sep; 52(5):e12651. PubMed ID: 31297902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.
    Chen Y; Yang J; Jin H; Wen W; Xu Y; Zhang X; Wang Y
    PeerJ; 2023; 11():e16237. PubMed ID: 37842043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma.
    Bai Y; Xiong L; Zhu M; Yang Z; Zhao J; Tang H
    Cancer Biomark; 2019; 24(3):371-382. PubMed ID: 30883337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma.
    Cai H; Liang J; Jiang Y; Wang Z; Li H; Wang W; Wang C; Hou J
    J Exp Clin Cancer Res; 2024 Mar; 43(1):69. PubMed ID: 38443991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
    Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
    Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biological function and clinical significance of long non-coding RNA
    Dong YY; Zheng XW; Mijiti M; Tian R; Guo QB; Wu YY; Gao W; Wen SX
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Mar; 58(3):240-249. PubMed ID: 36878503
    [No Abstract]   [Full Text] [Related]  

  • 36. Identification and analysis of genes associated with head and neck squamous cell carcinoma by integrated bioinformatics methods.
    Jin Y; Yang Y
    Mol Genet Genomic Med; 2019 Aug; 7(8):e857. PubMed ID: 31304688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and prognostic potential of PLEK2 in head and neck squamous cell carcinoma based on bioinformatics analysis.
    Wang J; Sun Z; Wang J; Tian Q; Huang R; Wang H; Wang X; Han F
    Cancer Med; 2021 Sep; 10(18):6515-6533. PubMed ID: 34331382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
    Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
    Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
    Liu F; Zhao X; Qian Y; Zhang J; Zhang Y; Yin R
    Biomed Pharmacother; 2017 Dec; 96():229-237. PubMed ID: 28987947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting oncogenic functions of miR-301a in head and neck squamous cell carcinoma by PI3K/PTEN and MEK/ERK pathways.
    Granda-Díaz R; Manterola L; Hermida-Prado F; Rodríguez R; Santos L; García-de-la-Fuente V; Fernández MT; Corte-Torres MD; Rodrigo JP; Álvarez-Teijeiro S; Lawrie CH; Garcia-Pedrero JM
    Biomed Pharmacother; 2023 May; 161():114512. PubMed ID: 36931033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.